Stahl quote: "Follow the FDA label and never get anybody better" [22:10] When GLP-1s aren't appropriate [24:01] Case study: patient on paliperidone gaining weight despite tirzepatide [25:52] Discovery of nucleus tractus solitaris [28:26] The "are we allowed to prescribe this?" debate [29:10] Valproic acid, propranolol, and scope of practice [30:01] Bipolar disorder, obesity, and mood episode frequency [30:49] Moving beyond the monoamine hypothesis [31:19] UK paper: no proof depression is serotonin deficiency [33:23] Alternative treatments: TMS, ketamine, GLP-1s [34:03] Dr
doi: 10.5483/BMBRep.2020.53.1.279 72 LiQLiuYSunM
A solar lentigo shares with a lentigo simplex the feature of hyperpigmentation of basilar keratinocytes
Mild side effects among them all include: Gastrointestinal issues: constipation, nausea, vomiting, diarrhea, bloating, gas, stomach pain/cramping, and general upset stomach Skin reactions: swollen, red or irritated skin at the injection site, or pigmentation (patches of darker skin) Mental health: signs on depression, increase in anxiety, brain fog, fatigue, headache, and dizziness Serious side effects are RARE, and if you experience any of the following to call your provider ASAP : Kidney issues Pancreatitis Gallbladder issues Thyroid issues Bowl obstruction Severe and lasting stomach pain/cramping Severe mental health such as thoughts of depression Blindness (in cases of existing diabetic retinopathy) * Note: This is just a list of possible side effects
Other pharmacotherapies for obesity management that were not indicated as potentially used off-label in BBS include lixisenatide, naltrexone and bupropion, lisdexamfetamine, and topiramate